Please assess the completion status of the following clinical trial:

Trial Title: Darbepoetin Administration to Preterm Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 500-1250 grams birth weight~* less than or equal to 32 weeks gestation~* less than 2 days of age~Exclusion Criteria:~* severe hemorrhagic disease~* severe hemolytic disease~* DIC~* seizures~* hypertension~* thromboses~* receiving erythropoietin

- Gender: ALL
- Minimum Age: 1 Hour
- Maximum Age: 49 Hours
- Healthy Volunteers: f

Study Arms:
- Darbepoetin alfa injection (Type: EXPERIMENTAL): Darbepoetin alfa 10 mics/kg/week subcutaneous injection x 10 weeks or until 35 completed weeks Drug: Darbepoetin alfa Other names: Aranesp Darbe SC injection
- erythropoietin alfa injection (Type: ACTIVE_COMPARATOR): Epo 400 units/kg three times a week SC x 10 weeks or until 35 completed weeks Drug: erythropoietin other names: epogen Epo SC injection
- placebo/control (Type: PLACEBO_COMPARATOR): Sham injection

Based on this trial design, predict the completion outcome and termination type (if applicable).